Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1)
Inflammatory cells are major players in the onset of cancer. The degree of inflammation and type of inflammatory cells in the tumor microenvironment (TME) are responsible for tilting the balance between tumor progression and regression. Cancer-related inflammation has also been shown to influence th...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1337 |
id |
doaj-edf59f3e6fdf4606b65323fe0a66eb74 |
---|---|
record_format |
Article |
spelling |
doaj-edf59f3e6fdf4606b65323fe0a66eb742020-11-25T03:05:36ZengMDPI AGCancers2072-66942020-05-01121337133710.3390/cancers12051337Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1)Federica Raggi0Maria Carla Bosco1Laboratory of Molecular Biology, IRCSS Istituto Giannina Gaslini, 16147 Genova, ItalyLaboratory of Molecular Biology, IRCSS Istituto Giannina Gaslini, 16147 Genova, ItalyInflammatory cells are major players in the onset of cancer. The degree of inflammation and type of inflammatory cells in the tumor microenvironment (TME) are responsible for tilting the balance between tumor progression and regression. Cancer-related inflammation has also been shown to influence the efficacy of conventional therapy. Mononuclear phagocytes (MPs) represent a major component of the inflammatory circuit that promotes tumor progression. Despite their potential to activate immunosurveillance and exert anti-tumor responses, MPs are subverted by the tumor to support its growth, immune evasion, and spread. MP responses in the TME are dictated by a network of stimuli integrated through the cross-talk between activatory and inhibitory receptors. Alterations in receptor expression/signaling can create excessive inflammation and, when chronic, promote tumorigenesis. Research advances have led to the development of new therapeutic strategies aimed at receptor targeting to induce a tumor-infiltrating MP switch from a cancer-supportive toward an anti-tumor phenotype, demonstrating efficacy in different human cancers. This review provides an overview of the role of MP receptors in inflammation-mediated carcinogenesis and discusses the most recent updates regarding their targeting for immunotherapeutic purposes. We focus in particular on the TREM-1 receptor, a major amplifier of MP inflammatory responses, highlighting its relevance in the development and progression of several types of inflammation-associated malignancies and the promises of its inhibition for cancer immunotherapy.https://www.mdpi.com/2072-6694/12/5/1337mononuclear phagocytestumor-associated macrophages and dendritic cellstumor microenvironmentcancer immunotherapypattern recognition and immunoregulatory receptorstriggering receptor expressed on myeloid cells |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Federica Raggi Maria Carla Bosco |
spellingShingle |
Federica Raggi Maria Carla Bosco Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) Cancers mononuclear phagocytes tumor-associated macrophages and dendritic cells tumor microenvironment cancer immunotherapy pattern recognition and immunoregulatory receptors triggering receptor expressed on myeloid cells |
author_facet |
Federica Raggi Maria Carla Bosco |
author_sort |
Federica Raggi |
title |
Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) |
title_short |
Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) |
title_full |
Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) |
title_fullStr |
Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) |
title_full_unstemmed |
Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) |
title_sort |
targeting mononuclear phagocyte receptors in cancer immunotherapy: new perspectives of the triggering receptor expressed on myeloid cells (trem-1) |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-05-01 |
description |
Inflammatory cells are major players in the onset of cancer. The degree of inflammation and type of inflammatory cells in the tumor microenvironment (TME) are responsible for tilting the balance between tumor progression and regression. Cancer-related inflammation has also been shown to influence the efficacy of conventional therapy. Mononuclear phagocytes (MPs) represent a major component of the inflammatory circuit that promotes tumor progression. Despite their potential to activate immunosurveillance and exert anti-tumor responses, MPs are subverted by the tumor to support its growth, immune evasion, and spread. MP responses in the TME are dictated by a network of stimuli integrated through the cross-talk between activatory and inhibitory receptors. Alterations in receptor expression/signaling can create excessive inflammation and, when chronic, promote tumorigenesis. Research advances have led to the development of new therapeutic strategies aimed at receptor targeting to induce a tumor-infiltrating MP switch from a cancer-supportive toward an anti-tumor phenotype, demonstrating efficacy in different human cancers. This review provides an overview of the role of MP receptors in inflammation-mediated carcinogenesis and discusses the most recent updates regarding their targeting for immunotherapeutic purposes. We focus in particular on the TREM-1 receptor, a major amplifier of MP inflammatory responses, highlighting its relevance in the development and progression of several types of inflammation-associated malignancies and the promises of its inhibition for cancer immunotherapy. |
topic |
mononuclear phagocytes tumor-associated macrophages and dendritic cells tumor microenvironment cancer immunotherapy pattern recognition and immunoregulatory receptors triggering receptor expressed on myeloid cells |
url |
https://www.mdpi.com/2072-6694/12/5/1337 |
work_keys_str_mv |
AT federicaraggi targetingmononuclearphagocytereceptorsincancerimmunotherapynewperspectivesofthetriggeringreceptorexpressedonmyeloidcellstrem1 AT mariacarlabosco targetingmononuclearphagocytereceptorsincancerimmunotherapynewperspectivesofthetriggeringreceptorexpressedonmyeloidcellstrem1 |
_version_ |
1724677626489995264 |